GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) and the Sickle Cell Disease Association of America (SCDAA) are co-hosting the 11th Annual Sickle Cell Disease Therapeutics Conference on September 14, 2022. The conference, held virtually during National Sickle Cell Awareness Month, features remarks from Admiral Rachel Levine, Assistant Secretary for Health, and discussions on the impact of Sickle Cell Disease (SCD) on patients and caregivers. Leading experts, advocates, and policymakers will explore unmet needs and trends in therapeutic development. Registration is open at scdconference.com.

Pfizer announced the acquisition of Global Blood Therapeutics (GBT) for $68.50 per share in cash, totaling approximately $5.4 billion. This acquisition aims to enhance Pfizer's portfolio in sickle cell disease (SCD), addressing critical needs in this underserved community. GBT's Oxbryta, a first-in-class SCD treatment, generated $195 million in net sales in 2021. The combined franchise from both companies could exceed $3 billion in peak sales worldwide. The deal awaits stockholder and regulatory approvals.

Global Blood Therapeutics (GBT) granted restricted stock units totaling 30,450 shares to 10 new employees on August 1, 2022. This action was part of GBT’s Amended and Restated 2017 Inducement Equity Plan, aimed at attracting talent in compliance with NASDAQ rules. GBT, focused on treatments for sickle cell disease, is advancing its pipeline with therapies like Oxbryta and inclacumab. The company continues to explore innovative treatments for underserved patient communities.

Global Blood Therapeutics (GBT) will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on August 10, 2022, at 2:20 p.m. E.T. The event will be live-streamed on GBT's website, with an archived replay available for one month. GBT, founded in 2011, focuses on developing treatments for sickle cell disease (SCD). The company has launched Oxbryta (voxelotor), the first FDA-approved medicine targeting SCD by inhibiting sickle hemoglobin polymerization and is advancing other pipeline programs aimed at improving care for SCD patients.

Global Blood Therapeutics (GBT) will release its Q2 2022 financial results on August 8, 2022, after U.S. markets close. Management will host a conference call at 4:30 p.m. ET on the same day to discuss results and provide a business update. Investors can participate by calling 877-407-3982 (domestic) or +1 201-493-6780 (international), and a live audio webcast will be available on GBT’s website. GBT aims to transform treatments for sickle cell disease through its approved medicine, Oxbryta, and ongoing clinical developments.

Global Blood Therapeutics has received marketing authorization from the MHRA for Oxbryta (voxelotor) in Great Britain, marking it as the first approved treatment directly targeting sickle hemoglobin polymerization, crucial for treating sickle cell disease (SCD). This oral therapy is intended for adults and children over 12, either alone or with hydroxycarbamide. The authorization follows promising results from the Phase 3 HOPE Study, demonstrating significant hemoglobin increases in patients. SCD affects 15,000 individuals in the UK, presenting ongoing health challenges.

Global Blood Therapeutics has launched an expanded access program (EAP) for voxelotor in Brazil, targeting adults and children aged 12 and older suffering from sickle cell disease (SCD). This initiative follows authorization by ANVISA, Brazil's health regulatory agency, with hopes to provide treatment options for an estimated 100,000 patients in the country who lack adequate therapies. Voxelotor, which aims to improve oxygen delivery and reduce hemolysis, will be available free of charge under this EAP, marking a significant step in addressing SCD in Brazil.

The GBT Foundation has awarded grants of $50,000 each to five community-based organizations (CBOs) through its inaugural Access to Care Empowerment for Sickle Cell (ACE) Grant Program. Total funding aims to be $250,000 annually to enhance health equity and support sickle cell disease (SCD) patients. Projects focus on education, peer support, and transition assistance for young adults with SCD. Since 2019, GBT has invested nearly $1.25 million across various organizations to improve care and access for those with SCD.

Global Blood Therapeutics (GBT) announced the grant of stock options and restricted stock units to 22 new employees on July 1, 2022. The aggregate options cover 10,600 shares at an exercise price of $32.80, along with 76,600 restricted stock units. These awards were part of GBT's Amended and Restated 2017 Inducement Equity Plan, following NASDAQ Listing Rule 5635(c)(4). GBT focuses on developing treatments for sickle cell disease and has introduced the FDA-approved Oxbryta, among other pipeline projects.